Silibinin mode(s) of action against hepatitis c virus: A controversy yet to be resolved

Hepatology

Volumn 54, Issue 2, 2011, Pages 749-749

  Dahari, Harel ^a,b   Guedj, Jeremie ^a   Perelson, Alan S ^a  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; MERICITABINE; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; SILIBININ; SILYMARIN;

ANTIVIRAL ACTIVITY; HEPATITIS C; LETTER; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS ENTRY; DRUG EFFECT; HEPATITIS C VIRUS; HUMAN; NOTE;

HEPACIVIRUS; HUMANS; SILYMARIN;

EID: 79960703901     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24310     Document Type: Letter

References (10)

1. Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 2010; 51: 1912-1921.
2. Wagoner J, Morishima C, Graf TN, Oberlies NH, Teissier E, Pécheur EI, et al. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS One 2011; 6: e16464.
3. Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 2010; 138: 1112-1122.
4. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135: 1561-1567.
5. Biermer M, Berg T. Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin. Gastroenterology 2009; 137: 390-391.
6. Payer BA, Reiberger T, Rutter K, Beinhardt S, Staettermayer AF, Peck-Radosavljevic M, et al. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient. J Clin Virol 2010; 49: 131-133.
7. Le Pogam S, Seshaadri A, Ewing A, Kang H, Kosaka A, Yan JM, et al. RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J Infect Dis 2010; 202: 1510-1519.
8. Guedj J, Rong L, Dahari H, Perelson AS. A perspective on modelling hepatitis C virus infection. J Viral Hepat 2010; 17: 825-833.
9. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107.
10. Dahari H, Barretto N, Sainz B Jr, Guedj J, Perelson AS, Uprichard SL. Modeling interferon-alpha mediated inhibition kinetics of intracellular and extracellular HCV RNA during HCV infection in vitro. J Hepatol 2011; 54( Suppl 1): S312.